Home » Stocks » NMRD

Nemaura Medical Inc. (NMRD)

Stock Price: $11.15 USD -1.12 (-9.13%)
Updated Jun 16, 2021 4:00 PM EDT - Market closed
Market Cap 271.97M
Revenue (ttm) n/a
Net Income (ttm) -5.47M
Shares Out 22.92M
EPS (ttm) -0.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 16
Last Price $11.15
Previous Close $12.27
Change ($) -1.12
Change (%) -9.13%
Day's Open 12.25
Day's Range 11.12 - 12.25
Day's Volume 253,112
52-Week Range 3.12 - 17.40

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Loughborough, England, June 01, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic dev...

2 weeks ago - GlobeNewsWire

Loughborough, England, May 26, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devi...

3 weeks ago - GlobeNewsWire

These penny stocks hit it out of the park in 2021 & continue to climb in May. The post Former Penny Stocks To Watch Making Their Mark In 2021 appeared first on Penny Stocks to Buy, Picks, News and Infor...

Other stocks mentioned: GTBP, OCGN
1 month ago - PennyStocks

Shares of Nemaura Medical Inc. (NASDAQ:NMRD) may be about to drop even more than they have so far today. On Wednesday, the bulls were firmly in control.

1 month ago - Benzinga

Nemaura Medical Inc. (NASDAQ: NMRD) shares are trading higher after the company receipt of a purchase order for 5,000 sugarBEAT transmitters and 200,000 sugarBEAT sensors from its U.K. licensee, DB Ethi...

1 month ago - Benzinga

Nemaura Medical Inc. (NASDAQ: NMRD), iBio, Inc. (NYSE: IBIO) and Cocrystal Pharma, Inc. (NASDAQ: COCP) are among the healthcare movers Wednesday. Nemaura Rallies On Receipt of Orders: Nemaura, a medtech...

Other stocks mentioned: IBIO, COCP
1 month ago - Benzinga

Loughborough, England, April 29, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-in...

1 month ago - GlobeNewsWire

Loughborough, England, April 21, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-in...

1 month ago - GlobeNewsWire

Loughborough, England, April 15, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-in...

2 months ago - GlobeNewsWire

Loughborough, England, March 25, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-in...

2 months ago - GlobeNewsWire

Loughborough, England, March 11, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-in...

3 months ago - GlobeNewsWire

Loughborough, England, March 10, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-in...

3 months ago - GlobeNewsWire

Loughborough, England, March 04, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-in...

3 months ago - GlobeNewsWire

Nemaura Medical Inc (NASDAQ:NMRD) has reported that it ended its third quarter with $14,959,785 in cash on the books as of December 31, 2020, up from $1,067,663 at the same stage a year earlier. The com...

4 months ago - Proactive Investors

Loughborough, England, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-inva...

4 months ago - GlobeNewsWire

Nemaura Medical Inc (NASDAQ:NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs...

4 months ago - Proactive Investors

Loughborough, England, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-inv...

4 months ago - GlobeNewsWire

Nemaura Medical (NMRD) stock is on the rise Monday with heavy trading despite a lack of news concerning the medical company. The post NMRD Stock: 8 Things to Know About Biopharma Nemaura Medical as Shar...

4 months ago - InvestorPlace

Loughborough, England, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-inv...

4 months ago - GlobeNewsWire

LOUGHBOROUGH, England, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-inv...

5 months ago - GlobeNewsWire

LOUGHBOROUGH, England, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-inva...

6 months ago - GlobeNewsWire

LOUGHBOROUGH, England, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-inva...

6 months ago - GlobeNewsWire

LOUGHBOROUGH, England, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-inva...

7 months ago - GlobeNewsWire

LOUGHBOROUGH, England, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-inva...

7 months ago - GlobeNewsWire

Clinically proven app from Healthimation , LLC , to be paired with Company’s pro BEAT ™ non-invasive CGM system solution to offer convenient and effective management of pre-diabetes and Type 2 ...

8 months ago - GlobeNewsWire

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable dia...

8 months ago - Business Wire

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devi...

9 months ago - Business Wire

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devi...

9 months ago - Business Wire

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devi...

9 months ago - Business Wire

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose monitor (...

9 months ago - Business Wire

Nemaura Medical (NASDAQ: NMRD) shares are trading lower on Tuesday after the company filed for a common stock offering of 1.6 million shares.

10 months ago - Benzinga

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devic...

10 months ago - Business Wire

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devic...

10 months ago - Business Wire

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devi...

10 months ago - Business Wire

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devi...

10 months ago - Business Wire

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devi...

11 months ago - Business Wire

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose monitor (...

11 months ago - Business Wire

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devi...

11 months ago - Business Wire

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devi...

11 months ago - Business Wire

There are a number of medical technology companies  that have gained momentum in an otherwise pessimistic market amid the Covid-19 pandemic.

1 year ago - GuruFocus

The company's continuous glucose monitor is a potential breakthrough in the diabetes diagnostics space, and also the reason why its stock has gained momentum

1 year ago - GuruFocus

Loughborough, England, Feb. 11, 2020 (GLOBE NEWSWIRE) --   Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible conti...

1 year ago - GlobeNewsWire

Loughborough, England, Dec. 20, 2019 (GLOBE NEWSWIRE) --  Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose ...

1 year ago - GlobeNewsWire

Nemaura and Changing Health to provide innovative digital education and personalized coaching to enhance outcomes for people with diabetes and prediabetes Nemaura and Changing Health to provide innovati...

1 year ago - GlobeNewsWire

BEAT® Diabetes utilizes SugarBEAT® CGM data to provide holistic coaching services via user-friendly app to enhance outcomes for diabetic and pre-diabetic patients  BEAT® Diabetes utilizes SugarBEAT® CGM...

1 year ago - GlobeNewsWire

Loughborough, England, Dec. 04, 2019 (GLOBE NEWSWIRE) --  Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasi...

1 year ago - GlobeNewsWire

Loughborough, England, Nov. 11, 2019 (GLOBE NEWSWIRE) --  – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-inv...

1 year ago - GlobeNewsWire

Loughborough, England , Sept. 12, 2019 (GLOBE NEWSWIRE) -- Loughborough, England – September 12, 2019 – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on ...

1 year ago - GlobeNewsWire

About NMRD

Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. The company provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as for screening pre-diabetic patients. It has a license agreement with Healthimation, LLC, which licenses the company to make, have made, use, offer to sell, sell, and import intensive medical diabetes and weight management program for Type 2 diabetes, prediabetes, and general wellne... [Read more...]

Industry
Medical Devices
Founded
2009
CEO
Dewan Chowdhury
Employees
17
Stock Exchange
NASDAQ
Ticker Symbol
NMRD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for NMRD stock is "Strong Buy" and the 12-month stock price forecast is 15.00.

Price Target
$15.00
Analyst Consensus: Strong Buy